MEDIA ADVISORY - POLITICAL RESPONSE TO THE SUPREME COURT OF CANADA DECISION REGARDING THE CONSTITUTIONAL VALIDITY OF AN ACT RESPECTING FIRST NATIONS, INUIT AND MÉTIS CHILDREN, YOUTH AND FAMILIES
WENDAKE, QC, Feb. 8, 2024 /CNW/ - Media representatives are invited to a press conference during which First Nations elected leadership will respond to the Supreme Court of Canada decision regarding An Act respecting First Nations, Inuit and Métis children, youth and families (C-92).
What: Press conference
Who:
Ghislain Picard, Chief of the Assembly of First Nations Quebec-Labrador (AFNQL)
Jean-Claude Mequish, Chief of the Conseil des Atikamekw d'Opitciwan
Derek Montour, President of the First Nations of Quebec and Labrador Health and Social Services Commission (FNQLHSSC)
Many First Nations Chiefs and elected leadership will also be present
When: Friday, February 9, 2024, at 10:45 a.m.
Where: Alt Hotel, located at 185 Slater Street, Ottawa | Room: Indigo
About the AFNQL
The Assembly of First Nations Quebec-Labrador is the political organization that brings together 43 Chiefs of the First Nations in Quebec and Labrador.
About the FNQLHSSC
The First Nations of Quebec and Labrador Health and Social Services Commission is a non-profit organization that supports Quebec First Nations in achieving their objectives in terms of health, wellness, culture, and self-determination.
SOURCE Assembly of First Nations of Quebec and Labrador
The latest product innovation by NICO Corporation is described as a "game-changing advancement" by neurosurgeons with early experience using the NICO Myriad SPECTRA System ? the ONLY hand-held technology delivering blue excitation light to enhance...
Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVEtm, to develop differentiated small molecule therapeutics, today announced that its...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024,...
Viridian Therapeutics, Inc. (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent...
Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to...
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...
